

# Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial

Ekkehard Grünig<sup>1\*†</sup>, Alison MacKenzie <sup>2†</sup>, Andrew J. Peacock <sup>2</sup>, Christina A. Eichstaedt<sup>1,3</sup>, Nicola Benjamin<sup>1</sup>, Robert Nechwatal <sup>4</sup>, Silvia Ulrich <sup>5</sup>, Stéphanie Saxer <sup>5</sup>, Maurizio Bussotti <sup>6</sup>, Marinella Sommaruga <sup>6</sup>, Stefano Ghio <sup>7</sup>, Lina Gumbiene <sup>8,9</sup>, Eglė Palevičiūtė<sup>8,9</sup>, Elena Jurevičienė<sup>8,9</sup>, Antonio Cittadini<sup>10</sup>, Anna A. Stanzola<sup>11</sup>, Alberto M. Marra <sup>1,12</sup>, Gabor Kovacs <sup>13,14</sup>, Horst Olschewski <sup>13,14</sup>, Joan-Albert Barberà<sup>15</sup>, Isabel Blanco<sup>15</sup>, Martijn A. Spruit <sup>16,17,18,19</sup>, Frits M.E. Franssen <sup>20</sup>, Anton Vonk Noordegraaf<sup>21</sup>, Abílio Reis <sup>22</sup>, Mário Santos <sup>22</sup>, Sofia Gonçalves Viamonte<sup>23</sup>, Heleen Demeyer <sup>24,25,26</sup>, Marion Delcroix <sup>24</sup>, Eduardo Bossone <sup>27‡</sup>, and Martin Johnson <sup>2‡</sup>

<sup>1</sup>Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Röntgenstraße 1, D-69126 Heidelberg, Germany; <sup>2</sup>Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK; <sup>3</sup>Laboratory for Molecular Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; <sup>4</sup>Rehabilitation Center Koenigstuhl, Heidelberg, Germany; <sup>5</sup>Clinic of Pulmonology, University Hospital and University of Zurich, Zurich, Switzerland; <sup>6</sup>Cardiac Rehabilitation Department, IRCCS Maugeri Clinical Scientific Institutes, Milan, Italy; <sup>7</sup>Divisione di Cardiologia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy; <sup>8</sup>Competence Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; <sup>9</sup>Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania; <sup>10</sup>Department of Translational Medical Sciences, "Federico II" University, Naples, Italy; <sup>11</sup>Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy; <sup>12</sup>Department of Cardiovascular Imaging, IRCCS S.D.N., Naples, Italy; <sup>13</sup>Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; <sup>14</sup>Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria; <sup>15</sup>Department of Pulmonary Medicine, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona and Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain; <sup>16</sup>Research and Development, Ciro, Horn, Netherlands; <sup>17</sup>Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands; <sup>18</sup>NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands; <sup>19</sup>REVAL—Rehabilitation Research Center, BIOMED—Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium; <sup>20</sup>Department of Research and Education, CIRO, Horn, The Netherlands; <sup>21</sup>Department of Pulmonology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands; <sup>22</sup>Department of Internal Medicine, Hospital Geral de Santo António, Porto, Portugal; <sup>23</sup>Centro de Reabilitação do Norte/Centro Hospitalar Vila Nova de Gaia Espinho, Porto, Portugal; <sup>24</sup>Department of Pneumology, University Hospital Leuven, Leuven, Belgium; <sup>25</sup>Department of Rehabilitation Sciences, KU Leuven - University of Leuven, Leuven, Belgium; <sup>26</sup>Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium; and <sup>27</sup>Department of Cardiology, Antonio Cardarelli Hospital, Naples, Italy

Received 21 January 2020; revised 7 April 2020; editorial decision 10 August 2020; online publish-ahead-of-print 24 November 2020

See page 2296 for the editorial comment on this article (doi: 10.1093/eurheartj/ehaa780)

## Aims

This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

## Methods and results

For the first time a specialized PAH/CTEPH rehabilitation programme was implemented in 11 centres across 10 European countries. Out of 129 enrolled patients, 116 patients (58 vs. 58 randomized into a training or usual care

<sup>†</sup>These authors contributed equally to this work.

<sup>‡</sup>These authors shared last authorship.

\* Corresponding author. Tel: +49-6221-396-8053, Fax: +49-6221-396-1209, Email: [Ekkehard.gruenig@med.uni-heidelberg.de](mailto:Ekkehard.gruenig@med.uni-heidelberg.de)


Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

control group) on disease-targeted medication completed the study [85 female; mean age  $53.6 \pm 12.5$  years; mean pulmonary arterial pressure  $46.6 \pm 15.1$  mmHg; World Health Organization (WHO) functional class II 53%, III 46%; PAH  $n=98$ ; CTEPH  $n=18$ ]. Patients of the training group performed a standardized in-hospital rehabilitation with mean duration of 25 days [95% confidence interval (CI) 17–33 days], which was continued at home. The primary endpoint, change of 6-min walking distance, significantly improved by  $34.1 \pm 8.3$  m in the training compared with the control group (95% CI, 18–51 m;  $P < 0.0001$ ). Exercise training was feasible, safe, and well-tolerated. Secondary endpoints showed improvements in quality of life (short-form health survey 36 mental health  $7.3 \pm 2.5$ ,  $P = 0.004$ ), WHO-functional class (training vs. control: improvement 9:1, worsening 4:3;  $\chi^2$   $P = 0.027$ ) and peak oxygen consumption ( $0.9 \pm 0.5$  mL/min/kg,  $P = 0.048$ ) compared with the control group.

## Conclusion

This is the first multicentre and so far the largest randomized, controlled study on feasibility, safety, and efficacy of exercise training as add-on to medical therapy in PAH and CTEPH. Within this study, a standardized specialized training programme with in-hospital start was successfully established in 10 European countries.

## Graphical Abstract



## Keywords

Pulmonary rehabilitation • Pulmonary hypertension • Exercise programme

## Introduction

Low-intensity exercise training for patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) has been shown to increase quality of life (QoL), exercise capacity, lower limb muscle strength, and possibly haemodynamics.<sup>1–3</sup> Up to date, 6 randomized controlled trials have been published<sup>2–7</sup> as well as 14 further controlled trials or cohort studies.<sup>8</sup> Hence, the evidence is mounting that exercise training is a valuable add-on to

targeted medical therapy. Currently, specialized low-dose exercise training holds a class IIa level B recommendation in the European Society of Cardiology/European Respiratory Society (ESC/ERS) pulmonary hypertension (PH) guidelines.<sup>9–11</sup>

Until the ESC/ERS-guidelines had been published, the sample sizes of the four randomized controlled studies in pre-capillary PH patients considered for recommendations on exercise training were quite small (ranging from 23 to 30 patients). After 2015, two further randomized controlled trials,<sup>2,5</sup> three meta- and one Cochrane

analysis<sup>12–15</sup> have shown that exercise training is highly beneficial for pre-capillary PH patients. In most previous studies, the initial training was highly supervised and conducted in an inpatient setting.<sup>8,9</sup> Therefore, PH guidelines recommended that exercise training programmes should be implemented by centres experienced in both—PAH patient care and rehabilitation of compromised patients. In addition, patients should be treated with the best standard of pharmacological treatment and in a stable clinical condition before embarking on supervised rehabilitation.<sup>9</sup> However, the access to such programmes is very limited and multicentre studies are lacking to assess the effect of exercise training in different countries with different healthcare systems. Before the start of this trial, rehabilitation was not available for PH patients in most European countries.

Therefore, the objective of this study was to perform a multicentre, randomized, controlled trial across Europe also including countries in which exercise training had so far not been available for PH patients to investigate its feasibility, safety, and efficacy. Furthermore, we aimed to develop and assess standardized settings, monitoring, and adjustment of exercise training which would be helpful to implement a validated, high-quality programme with a solid scientific evaluation.

## Methods

### Study population and design

All participating centres were members of a European Respiratory Society Task Force on exercise training in PH.<sup>8</sup> A common protocol was designed to conduct the first multicentre study on exercise training in PH. Eleven centres from 10 European countries (Austria, Belgium, Germany, Italy, Lithuania, the Netherlands, Portugal, Scotland, Spain, and Switzerland) participated.

Inclusion criteria were pre-capillary PH [PAH or non-operable or recurrent chronic thromboembolic PH (CTEPH)] diagnosed by right heart catheterization according to the ESC/ERS PH guidelines.<sup>9</sup> Study participants had to be  $\geq 18$  years of age, non-pregnant, in World Health Organization functional class (WHO-FC) II–IV and stable on optimized PAH targeted therapy for at least 2 months prior to study enrolment. Excluded were patients with PAH associated with portal hypertension, complex congenital heart disease,<sup>16</sup> HIV and patients with pulmonary veno-occlusive disease. Further exclusion criteria were clinically relevant lung or left heart disease, active liver disease, acute infection, walking disability, haemoglobin concentration below 75% of lower limit of normal values (individual age and gender adjusted normal values of haemoglobin), systolic blood pressure  $< 85$  mmHg, recent syncope and skeletal or muscle abnormalities prohibiting participation in an exercise programme. Patients with sustained supraventricular and ventricular arrhythmias at baseline were not enrolled into the study. Patients with mild non-sustained supraventricular or ventricular arrhythmias or with a history of arrhythmia, e.g. after cardioversion, were able to participate in the study. Targeted PAH or other medication was not to be altered within the training period. The study complies with the Declaration of Helsinki. All patients gave their written informed consent to the study. The study was approved by the ethics committee of the Medical Faculty of Heidelberg University, Germany (S-473/2015) and by each centre's respective ethics committee. The study was registered in clinicaltrials.gov under the identifier NCT03345212.

### Randomization and outcome measures

The study was a 15-week, randomized, controlled multicentre trial. After giving written informed consent for this study, patients were randomly assigned to either a 'training group' or a 'control group' using a permuted block randomization procedure with sealed envelopes, stratified by centre. Patients of the training group stayed in-house for the initial 10–30 days of the study period and continued with a programme at home for another 11–12 weeks. Patients of the control group stayed at home with usual daily activity. Efficacy parameters were assessed at baseline and after 15 weeks by investigators who were blinded to the clinical data.


The primary endpoint was the change in 6-min walking distance (6MWD) from baseline to 15 weeks between exercise training and control group. Six-minute walk test was carried out under standardized conditions.<sup>17</sup>

Secondary endpoints were the change from baseline to 15 weeks after rehabilitation in peak oxygen consumption based on a cardiopulmonary exercise testing (CPET), WHO-FC, N-terminal prohormone brain natriuretic peptide (NT-proBNP), QoL, and safety parameters. Echocardiography at rest and during exercise and CPET were performed in a smaller subset of centres. Assessment and analysis of QoL (short-form health survey 36, SF-36 questionnaire) and of other efficacy parameters were performed as described previously.<sup>2</sup> Adverse events, defined according to International Conference of Harmonization Good Clinical Practice, during the study period were recorded.

### Exercise training programme

For standardization of the training programme great effort has been undertaken including several meetings of the participating professionals and the implementation of a train the trainer setting. At least one PH expert and physiotherapist from each centre spent several days at the PH expert centre and rehabilitation clinic in Heidelberg, Germany between November 2014 and April 2018 to receive first-hand experience on the set-up of the clinical examinations, patients' exercise capacity evaluation, training adjustment, monitoring, and exercise training components to assimilate procedures across countries as much as possible. The 6MWD as primary endpoint was performed standardized according to current recommendations.<sup>18</sup> Each centre performed a study entrance examination to assess baseline parameters, enabled an inpatient phase between 10 and 30 days followed by an outpatient phase until the final examination at 15 weeks.

The exercise and respiratory training was based on published procedures<sup>2,3</sup> and adapted by each country to achieve a feasible set-up which was similar to the described setting. The Heidelberg exercise training programme specifically developed for patients with PH was chosen as intervention due to the profound scientific evaluation of the programme and safety reasons (low intensity). The training programme consisted of respiratory therapy, cycle ergometer training, dumbbell training, guided walks, and mental training as described previously.<sup>2</sup> During the initiation period, exercise training was performed 5–7 times/week. During the continuation phase at home, training frequency was 3–7 times/week. Training intensity was 40–60% of the patients' achieved maximal workload during ergometer test at baseline. Oxygen saturation, heart rate, right ventricular function at rest and during exercise, and subjective perception were considered for initial training intensity and training adjustment. Right ventricular function during exercise was measured by echocardiography as visual estimation of pump function and as change of systolic pulmonary arterial pressure from rest to peak exercise measured during stress echocardiography as described previously.<sup>19</sup> Pump function was classified qualitatively as normal, mildly, moderately, or severely impaired. Training was closely supervised by physical therapists and physicians specialized in rehabilitation medicine and PH experts. Transcutaneous oxygen saturation and heart rate were monitored continuously throughout the training. Patients, who were on oxygen therapy 16–24 h/day before inclusion



**Figure 1** Study flow-chart. This flow-chart gives the course of the study, patient randomization, assessments, and definition of dropouts. 6MWD, 6-min walking distance; AE, adverse event; CI, confidence interval; CO, cardiac output; CTEPH, chronic thromboembolic pulmonary hypertension; FU, follow-up; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension.

into this study remained on oxygen during the training programme. At discharge at the end of the inpatient phase, patients received an individualized training manual and organized a cycle ergometer for use at home.

## Statistical methods

The analyses were performed by a statistician (N.B.). The efficacy analysis and subject characterization were performed by use of the efficacy dataset including all patients with baseline and follow-up assessment of the primary endpoint 6MWD. All patients who were enrolled and randomized into the study were included in the safety analysis. Data are given as mean values  $\pm$  standard deviations. For the description of effects changes in absolute values were calculated. Differences between changes of the intervention and the control group were calculated and expressed as 'control-group corrected change'.

Calculation of sample size was based on the primary efficacy endpoint which was defined as the change in 6MWD between baseline and 15 weeks of exercise training between the training and the control group. To detect a control-group adjusted difference in 6MWD of 30 m, with an equal standard deviation of 53 m with a power of 80% and a two-sided significance level of 5%, it was calculated that 50 patients were required in each treatment arm. Under consideration of the assumed dropout rate of 20%, the sample size was increased to 63 patients in each group (total 126). The primary efficacy analysis was performed by a *t*-test with unequal variances (Welch tests) of changes between groups since the assumption

for a covariance analysis was not fulfilled. The frequency of patients with increase of 6MWD  $\geq 10\%$  and the frequency of patients with increase above 440 m (low-risk category according to ESC/ERS risk stratification)<sup>9</sup> was analysed for interpretation of the primary endpoint.

Secondary endpoints were tested with two-sided student's *t*-tests for unequal variances. For analysis of categorical data,  $\chi^2$  test was used. No imputation strategy was implemented for missing data. A sensitivity analysis excluding outliers  $>1.5$  of interquartile range was performed for the primary endpoint 6MWD and for peak  $\text{VO}_2$ .

Safety was analysed descriptively. Adverse events (AEs) during the study period included all AEs that started or worsened from baseline until the last visit (15 weeks). As one centre did not report AEs for the control group, patients from this centre were excluded from analysis of AEs. All tests were two-sided and *P*-values  $<0.05$  were considered statistically significant. All analyses were carried out with IBM SPSS V25 (IBM Corp. Armonk, NY, USA).

## Results

### Study population

From October 2015 until November 2019, a total of 129 patients were enrolled into the study with 61 patients in the control group and 68 patients in the training group (Figure 1, Supplementary



material online, Table S1). Out of them, 116 completed the study with baseline and follow-up assessment of the primary endpoint 6MWD (58 vs. 58 patients; 73.3% female,  $53.6 \pm 12.5$  years, 47.5% WHO-FC  $\geq 3$ , mean pulmonary artery pressure  $47 \pm 15$  mmHg, pulmonary vascular resistance  $8.2 \pm 5.0$  WU; Table 1). One patient in the training group and one patient in the control group had mild impairment of left ventricular function. Right ventricular function was mildly impaired in 13 vs. 10, moderately impaired in 5 vs. 5, and severely impaired in 3 vs. 2 patients (training vs. control). Reasons for dropout are given in Figure 1. Mean inpatient training duration was 25 days [95% confidence interval (CI) 17 to 33 days]. Pulmonary hypertension-specific medication was not changed throughout the study period. Baseline parameters were well-balanced between groups (Table 1).

## Primary endpoint 6MWD

Patients of the training group showed a significant improvement of the primary endpoint 6MWD ( $30.7 \pm 57.9$  m), while the control group slightly decreased in 6MWD ( $-3.4 \pm 25.9$  m; control-group corrected change  $34.1 \pm 8.3$  m;  $P < 0.0001$ , Table 1 and Figure 2). In the training group, 19 patients (32.3%) had a walking distance improvement  $\geq 10\%$ , compared with two patients (3.4%) in the control group. Twenty-five patients from the training group vs. one patient in the control group showed a 6MWD improvement above the threshold of clinically important difference  $\geq 33$  m.

Ten patients of the training group who presented with a walking distance  $< 440$  m at baseline improved their walking distance to  $\geq 440$  m during follow-up (ESC/ERS low-risk category), three patients showed deterioration of walking distance below this threshold. In comparison, one patient from the control group improved walking distance from  $< 440$  m to  $\geq 440$  m, while three patients showed deterioration below the threshold.

## Secondary endpoints

Quality-of-life scores (mental health) significantly improved in the training group, compared with the control group (control-group corrected change  $7.3 \pm 2.5$ ;  $P = 0.004$ ) and improved in trend for physical functioning ( $P = 0.07$ ) and social functioning ( $P = 0.09$ ; Figure 3). With Bonferroni correction,  $P$ -values  $< 0.005$  remained statistically significant for QoL data. Other SF-36 scales and subscales did not significantly differ between groups.

In the training group, nine patients improved in WHO-FC, compared with one patient in the control group; four patients worsened in WHO-FC, compared with three patients in the control group ( $\chi^2 P = 0.027$ ).

In CPET peak oxygen consumption significantly improved in the training group [control-group corrected change  $+0.9 \pm 0.3$  mL/min/kg;  $P = 0.048$ ; Figure 4; improvement equals  $8.5 \pm 17.6\%$  in the training group vs.  $1.0 \pm 13.8\%$  in the control group ( $P = 0.015$ )]. In the training group, 23 patients (41.8%) had a peak oxygen consumption improvement  $\geq 10\%$ , compared with 15 patients (28.3%) in the control group.

Patients in the training group had a significant decrease in systolic pulmonary arterial pressure ( $-4$  mmHg) compared with the control group ( $+5.8$  mmHg; difference  $9.8 \pm 3.1$  mmHg,  $P = 0.002$ , Table 2). Other echocardiographic parameters did not show significant differences between respective changes compared with baseline.

Other parameters from CPET and change of NT-proBNP showed no significant differences between groups (Table 2).

Sensitivity analysis excluding outliers revealed that the primary endpoint 6MWD (difference  $26.3 \pm 6.5$  m,  $P = 0.0001$ ) and peak  $\text{VO}_2$  (difference  $0.75 \pm 0.38$  mL/min/kg,  $P = 0.05$ ) still remained statistically significant.

## Safety

The safety set comprised 99 patients, as AEs from one centre ( $n = 30$ ), which only reported AE data for patients from the intervention group, were excluded. In total, 52 AEs (27 training group, 25 control group) were reported for 21 patients (13 training group and 8 control group). Adverse events with a frequency of  $\geq 5\%$  and serious AEs were comparable between groups (Table 3). The most frequent AEs were arrhythmia and respiratory infections. In the training group, three patients experienced a serious AE during the study period, compared with one in the control group ( $\chi^2 P = 0.38$ ). All serious AEs were classified as serious due to occurrence of hospitalization.

Patients of the training group showed a higher dropout rate for the efficacy dataset ( $\chi^2 P = 0.095$ ), though three patients successfully completed the study, but did not perform a 6MWD due to organizational issues. No patient in the control group vs. four patients in the training group did not complete the study due to AEs, out of which one was a serious AE (decompensated diabetes). However, none of the AEs or serious AEs were evaluated to be related to the study intervention.

## Discussion

This is the first randomized controlled multicentre study on exercise training in patients with pre-capillary PH, performed in 11 centres in 10 European countries in a large patient population, showing a significant and clinically meaningful improvement of the primary endpoint 6MWD and of the secondary endpoints WHO-FC, QoL, and peak oxygen consumption. The study showed for the first time that a safe and effective exercise training programme can be standardized and is feasible in different countries with different healthcare systems. To make this therapy widely available for PH patients participating centres implemented this PH training programme mostly for the first time and successfully adapted it to their local healthcare system.

## Significant improvement of primary endpoint 6MWD

The effects of exercise training have so far been investigated by only a few working groups, which raised the need for larger and multicentre studies to verify the results.<sup>8,12,20</sup>

Although the 6MWD as outcome parameter has been criticized, particularly in add-on treatments,<sup>21</sup> we chose this patient-relevant outcome to reflect patients' exercise capacity as it has been shown that the 6MWD highly correlates with daily activity, haemodynamics and prognosis in PH and is thus used for risk assessment. Change in 6MWD has been reported to be below the clinically relevant threshold in several studies, despite significant changes in other relevant outcomes.<sup>21</sup> In a meta-analysis, the 6MWD has shown limitations as surrogate endpoint for clinical worsening events in PAH, but still a

**Table 1** Demographics and clinical characteristics of patients

Characteristic	Control group (n = 58)			Training group (n = 58)			Efficacy dataset (n = 116)		
	Mean $\pm$ SD or n and %	95% confidence interval	n	Mean $\pm$ SD or n and %	95% confidence interval	n	Mean $\pm$ SD or n and %	95% confidence interval	n
Age (years)	55.0 $\pm$ 12.7	(51.6 to 58.3)		52.3 $\pm$ 12.4	(49.1 to 55.6)		53.6 $\pm$ 12.5	(51.3 to 55.9)	
Height (cm)	164.6 $\pm$ 8.4	(162.4 to 166.8)		167.2 $\pm$ 9.9	(164.6 to 169.8)	57	165.9 $\pm$ 9.2	(164.2 to 167.6)	115
Weight (kg)	73.4 $\pm$ 12.9	(70.0 to 76.8)		77.7 $\pm$ 19.8	(72.4 to 82.9)	57	75.5 $\pm$ 16.8	(72.4 to 78.6)	115
Female sex number (%)	45 (77.6%)			40 (69.0%)			85 (73.3%)		
Pulmonary hypertension diagnosis									
Idiopathic or heritable PAH	34 (58.6%)			39 (67.2%)			73 (62.9%)		
Congenital heart disease-associated PAH	4 (6.9%)			5 (8.6%)			8 (6.9%)		
Connective tissue disease-associated PAH	8 (13.8%)			4 (6.9%)			12 (10.3%)		
Other type of PAH	1 (1.7%)			2 (3.4%)			3 (2.6%)		
PH due to lung disease	0			1 (1.7%)			1 (0.9%)		
Chronic thromboembolic pulmonary hypertension	11 (19.0%)			7 (12.1%)			18 (15.5%)		
PH-targeted drugs									
Calcium channel blockers	3 (5.2%)			9 (15.5%)			12 (10.3%)		
Phosphodiesterase 5-inhibitors	43 (74.1%)			45 (77.6%)			88 (75.9%)		
Endothelin receptor antagonists	49 (84.5%)			46 (79.3%)			95 (81.9%)		
Soluble guanylate cycle stimulator	8 (13.8%)			6 (10.3%)			14 (12.1%)		
Prostacyclin	10 (17.2%)			18 (31.0%)			28 (24.1%)		
IP receptor agonist	2 (3.5%)			2 (3.5%)			4 (3.5%)		
Medication combination treatment									
One drug	14 (24.1%)			12 (20.7%)			26 (22.4%)		
Two drugs	29 (50.0%)			24 (41.4%)			53 (45.7%)		
Three drugs	15 (25.9%)			21 (36.2%)			36 (31.0%)		
Four drugs	0			1 (1.7%)			1 (0.1%)		
Right heart catheterization									
Right atrial pressure (mmHg)	7.9 $\pm$ 4.5	(6.6 to 9.2)	51	6.5 $\pm$ 4.1	(5.4 to 7.7)	51	7.2 $\pm$ 4.3	(6.4 to 8.1)	102
Mean pulmonary arterial pressure (mmHg)	46.7 $\pm$ 14.9	(42.7 to 50.6)		46.5 $\pm$ 15.5	(42.4 to 50.6)	57	46.6 $\pm$ 15.1	(43.8 to 49.4)	115
Cardiac output (L/min)	5.2 $\pm$ 1.4	(4.8 to 5.6)	52	5.1 $\pm$ 1.5	(4.7 to 5.5)	53	5.2 $\pm$ 1.5	(4.9 to 5.45)	105
Cardiac index (L/min/m <sup>2</sup> )	2.8 $\pm$ 0.7	(2.6 to 3.0)	52	2.7 $\pm$ 0.7	(2.5 to 2.9)	54	2.8 $\pm$ 0.7	(2.6 to 2.9)	106
Pulmonary arterial wedge pressure (mmHg)	9.9 $\pm$ 3.4	(9.0 to 10.9)	53	9.1 $\pm$ 3.7	(8.1 to 10.1)	55	9.5 $\pm$ 3.6	(8.8 to 10.2)	108
Pulmonary vascular resistance (WU)	7.7 $\pm$ 4.5	(6.4 to 9.0)	49	8.6 $\pm$ 5.5	(7.1 to 10.2)	52	8.2 $\pm$ 5.0	(7.2 to 9.2)	101


Continued

Table 1 Continued


Characteristic	Control group (n = 58)			Training group (n = 58)			Efficacy dataset (n = 116)		
	Mean ± SD or n and %	95% confidence interval	n	Mean ± SD or n and %	95% confidence interval	n	Mean ± SD or n and %	95% confidence interval	n
WHO-FC class number (%)									
I	0			1 (1.7%)			1 (0.9%)		
II	34 (58.6%)			26 (44.8%)			60 (51.7%)		
III	24 (41.4%)			30 (51.7%)			54 (46.6%)		
IV	0			1 (1.7%)			1 (0.9%)		
Laboratory									
NT-proBNP (ng/L)	332.5 ± 480.6	(184.6 to 480.4)	43	686.0 ± 031.0	(342.2 to 1029.7)	37	460.0 ± 799.2	(318.2 to 673.8)	80
6-min walking test									
6MWD (m)	447.4 ± 120.2	(415.8 to 479.0)		447.2 ± 117.7	(416.2 to 478.1)		447.3 ± 118.4	(425.5 to 469.1)	
Cardiopulmonary exercise testing (CPET)									
with stress echocardiography									
Heart rate at rest (l/min)	78.7 ± 14.3	(74.3 to 83.2)	42	83.9 ± 14.0	(79.7 to 88.2)	44	81.4 ± 14.3	(78.3 to 84.4)	86
SaO <sub>2</sub> at rest (%)	95.4 ± 4.6	(93.9 to 96.8)	41	93.2 ± 11.8	(89.6 to 96.9)	42	94.3 ± 9.0	(92.3 to 96.2)	83
Peak heart rate (l/min)	123.0 ± 23.3	(115.8 to 130.1)	43	134.1 ± 22.9	(127.2 to 141.1)	44	128.6 ± 23.6	(123.6 to 133.6)	87
Peak SaO <sub>2</sub> (%)	90.0 ± 7.2	(87.7 to 92.2)	41	90.5 ± 7.1	(88.3 to 92.7)	43	90.2 ± 7.1	(88.7 to 91.8)	84
Peak VO <sub>2</sub> (mL/min/kg)	15.3 ± 4.3	(14.2 to 16.5)	53	14.2 ± 5.2	(12.8 to 15.6)		14.7 ± 4.8	(13.8 to 15.6)	111
Peak VO <sub>2</sub> % predicted (%)	68.5 ± 20.8	(61.9 to 75.0)	41	68.7 ± 51.5	(52.9 to 84.6)	43	68.6 ± 39.4	(60.1 to 77.2)	84
Peak workload (W)	81.6 ± 30.2	(71.9 to 91.2)	40	81.2 ± 27.1	(79.3 to 89.4)	44	81.4 ± 28.4	(75.2 to 87.5)	84
Workload % predicted (%)	74.8 ± 30.4	(65.0 to 84.5)	40	65.3 ± 29.0	(56.4 to 74.2)	43	69.9 ± 29.9	(63.4 to 76.4)	83
V'E/VC <sub>02</sub> slope	45.4 ± 11.1	(41.6 to 49.3)	35	46.2 ± 12.9	(41.6 to 50.7)	33	45.8 ± 11.9	(42.9 to 48.7)	68
Echocardiography									
sPAP (mmHg)	59.1 ± 23.3	(51.3 to 66.8)	37	65.6 ± 27.8	(56.8 to 74.3)	41	62.5 ± 25.8	(56.7 to 68.3)	78
TAPSE (mm)	2.1 ± 0.4	(2.0 to 2.3)	41	2.1 ± 0.4	(2.0 to 2.2)	43	2.1 ± 0.4	(2.0 to 2.2)	84
RA area (cm <sup>2</sup> )	21.1 ± 9.0	(18.1 to 24.0)	38	21.6 ± 8.6	(18.9 to 24.3)	41	21.4 ± 8.8	(19.4 to 23.3)	79
RV area (cm <sup>2</sup> )	23.3 ± 6.1	(21.0 to 25.6)	29	26.0 ± 7.9	(23.2 to 28.7)	33	24.7 ± 7.1	(22.9 to 26.5)	62
Quality of life (SF-36 Questionnaire)									
Physical summation score	45.6 ± 19.5	(40.1 to 51.1)	55	45.4 ± 19.0	(40.3 to 50.6)	50	45.5 ± 19.1	(41.8 to 49.2)	105
Mental summation score	56.9 ± 18.7	(51.6 to 62.2)	55	57.7 ± 21.3	(51.9 to 63.4)	50	57.3 ± 20.0	(53.4 to 61.2)	105
Physical functioning	53.7 ± 22.6	(47.5 to 59.9)	57	46.3 ± 24.5	(39.8 to 52.8)	53	49.9 ± 23.8	(45.4 to 54.4)	110
Physical role functioning	50.5 ± 40.9	(39.2 to 61.7)	57	39.9 ± 41.2	(29.0 to 50.8)	53	45.0 ± 45.0	(37.2 to 52.8)	110
Bodily pain	69.2 ± 29.6	(61.1 to 77.4)	57	71.0 ± 27.0	(63.8 to 78.2)	53	70.2 ± 70.2	(64.8 to 75.5)	110
General health perceptions	40.7 ± 19.7	(35.2 to 46.1)	57	46.6 ± 21.4	(41.0 to 52.3)	53	43.8 ± 20.7	(39.9 to 47.7)	110
Vitality	52.9 ± 20.2	(47.4 to 58.5)	57	54.7 ± 22.9	(48.7 to 60.8)	53	53.9 ± 21.6	(49.8 to 57.9)	110
Social role functioning	72.9 ± 25.6	(65.6 to 80.2)	57	69.8 ± 28.3	(62.2 to 77.3)	53	71.3 ± 27.4	(66.1 to 76.4)	110
Emotional role functioning	71.7 ± 37.8	(61.3 to 82.1)	57	66.1 ± 43.0	(54.7 to 77.5)	53	68.8 ± 40.5	(61.1 to 76.4)	110
Mental health	72.5 ± 17.6	(67.6 to 77.3)	57	72.0 ± 21.1	(66.4 to 77.6)	53	72.2 ± 19.4	(68.6 to 75.9)	110

In case of missing values, sample sizes are given in the column of n.

6MWD, 6-min walking distance; NT-proBNP, N-terminal pro brain natriuretic peptide; PH, pulmonary hypertension; RA, right atrial; RV, right ventricular; SaO<sub>2</sub>, oxygen saturation; SD, standard deviation; sPAP, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion; V'E/VC<sub>02</sub>, minute ventilation/carbon dioxide production; VO<sub>2</sub>, oxygen consumption; WHO-FC, World Health Organization functional class.



**Figure 2** Primary endpoint 6-min walking distance. Patients of the training group significantly improved in 6MWD compared with the control group by  $34.1 \pm 8.3$  m ( $P < 0.0001$ ).




**Figure 3** Secondary endpoints: quality of life. The secondary endpoint quality of life (QoL) significantly improved in the subscale mental health in the training group compared with the control group ( $P = 0.004$ ). Two further subscales were significant in trend (physical function  $P = 0.07$ , social function  $P = 0.09$ ).

difference of 22.4 m favoured active treatment.<sup>22</sup> In our study, clinically relevant improvement in 6MWD was supported by significant improvement of WHO-functional class and peak  $\text{VO}_2$ , which have both shown to be prognostically important and are included in the ERS/ESC risk stratification model for PAH. Though 6MWD may not be

directly linked to clinical worsening events, it does represent physical exercise capacity and may, together with other parameters, be interpreted for risk stratification and QoL.<sup>23</sup>

Our findings are also in line with previous studies on exercise training in PH<sup>8,12-15</sup> and confirm the positive results in a multicentre setting





**Figure 4** Secondary endpoints: peak oxygen consumption/kg. Peak oxygen consumption ( $\text{VO}_2$ )/kg body weight significantly improved by  $0.9 \pm 0.5$  mL/min/kg in the training group compared with the control group ( $P = 0.048$ ).

with an inpatient start of exercise training. Moreover, this study is the largest trial of PH patients undergoing exercise rehabilitation, substantially increasing the number of patients with scientifically evaluated training effects. The improvement of 6MWD by  $34.1 \pm 8.3$  m was clinically meaningful and lies above the threshold for clinical importance of 33 m in PH.<sup>24</sup> Ten patients of the training group (17.2%) improved walking distance to the low-risk category, according to ESC/ERS risk stratification. Mean 6MWD improvement was also comparable to results of medication studies in PAH,<sup>25</sup> and lies above the results of add-on medication in PAH with mean improvements of 19.96 m (95% CI 15.35–24.57 m).<sup>26</sup> The improvement of 6MWD is slightly lower than reported from other exercise training studies, which may also be attributed to the multicentricity of this study, the required adaptation of training protocols. It has already been shown that patients with high functional impairment, e.g. WHO-FC III and IV, show the most pronounced benefit by exercise training,<sup>27</sup> which may have influenced the results. As 25/58 patients of the training group and 26/58 patients of the control group already presented with 6MWD values  $\geq 440$  m at baseline, the improvement of walking distance may well be limited by a ceiling effect.<sup>28</sup> Furthermore, exercise training in PH was implemented for the first time in most of the centres, possibly resulting in suboptimal increase of training intensities, likely resulting in a lower training effect. To this end, the low number of AEs does support the focus on safety and tolerability of exercise training in this study.

### Improvement of secondary endpoints

Secondary efficacy parameters such as QoL and peak oxygen consumption significantly improved in the training group compared with the control group. As peak oxygen consumption showed a significant

increase, but workload and peak heart rate remained constant, the effect may be attributed to an economization of oxygen metabolism in the muscles. Patients of the control group improved peak  $\text{VO}_2 > 10\%$  in 29% of cases, which may possibly be attributed to the Hawthorne effect, which describes the change of behaviour that occurs in clinical trials due to the awareness of being observed. The improvement of physical and mental health parameters in this study underlines the holistic approach of exercise training to enable deconditioned PH patients to extend their individual daily activity spectrum. As NT-proBNP was not significantly increased in the training group, the exercise training also did not seem to have a negative impact on right heart insufficiency and ventricular load.

### Implementation of exercise training in different countries

To implement the standardized training programme mostly for the first time in the respective European countries new collaborations were initiated between PH expert centres and rehabilitation centres, funding opportunities were sought as the in-hospital rehabilitation was not part of reimbursement schemes of most national insurance systems. Thus, this study was the first step to enable a permanent implementation of an exercise training programme for PH patients in the respective European countries.

### Limitations

We cannot exclude a potential inclusion bias whereby patients who are willing to undertake an exercise intervention may reflect a more motivated and adherent group. Another limitation of this study is the amount of missing data including non-invasive haemodynamics. The number of values included for each parameter is reported to indicate

**Table 2** Changes in exercise testing and quality-of-life parameters

Characteristic	Control group (n = 58)			Training group (n = 58)			P-value*	Control-group corrected change		
	Mean $\pm$ SD or n and %	95% confidence interval	n	Mean $\pm$ SD or n and %	95% confidence interval	n		Mean $\pm$ SD or n and %	95% confidence interval	n
Laboratory										
NT-proBNP (ng/L)	79.4 $\pm$ 195.5	(15.1 to 143.6)	38	16.5 $\pm$ 297.8	(-90.9 to 123.9)	32	0.31	62.9 $\pm$ 59.4	(-55.6 to 181.3)	70
6MWT	-3.4 $\pm$ 25.9	(-10.2 to 3.4)		30.7 $\pm$ 57.9	(15.4 to 45.9)		<0.0001	34.1 $\pm$ 8.3	(-50.6 to -17.5)	
Cardiopulmonary exercise testing (CPET)										
Heart rate at rest (/min)	-1.4 $\pm$ 12.4	(-5.3 to 2.4)	42	-0.1 $\pm$ 14.1	(-4.5 to 4.4)	39	0.64	1.4 $\pm$ 2.9	(-7.2 to 4.4)	83
SaO <sub>2</sub> at rest (%)	-0.1 $\pm$ 2.7	(-1.0 to 0.8)	39	2.3 $\pm$ 10.4	(-1.1 to 5.6)	41	0.17	2.4 $\pm$ 1.7	(-5.9 to 1.1)	78
Peak heart rate (/min)	4.9 $\pm$ 19.1	(-1.0 to 10.8)	43	3.6 $\pm$ 12.5	(-0.4 to 7.5)	40	0.70	-1.4 $\pm$ 3.5	(-5.6 to 8.3)	83
Peak SaO <sub>2</sub> (%)	-0.8 $\pm$ 5.7	(-2.7 to 1.1)	38	-0.5 $\pm$ 3.2	(-1.6 to 0.5)	38	0.80	0.3 $\pm$ 1.1	(-2.4 to 1.8)	78
Peak VO <sub>2</sub> (mL/min/kg)	0.0 $\pm$ 2.3	(-0.7 to 0.6)	53	0.9 $\pm$ 2.5	(0.3 to 1.6)	55	0.05	0.9 $\pm$ 0.5	(-1.9 to 0.0)	108
Peak VO <sub>2</sub> % predicted (%)	2.3 $\pm$ 8.0	(-0.2 to 4.9)	39	4.6 $\pm$ 10.2	(1.3 to 7.9)	39	0.28	-2.3 $\pm$ 2.0	(-6.4 to 1.9)	78
Peak workload (Watt)	3.7 $\pm$ 13.7	(-0.7 to 8.1)	40	4.6 $\pm$ 15.3	(-0.3 to 9.4)	41	0.80	0.8 $\pm$ 3.2	(-7.3 to 5.6)	81
Peak workload % predicted (%)	3.7 $\pm$ 12.5	(-0.3 to 7.7)	40	2.4 $\pm$ 10.8	(-1.1 to 5.8)	40	0.61	1.3 $\pm$ 2.6	(-3.9 to 6.5)	80
VE/VCO <sub>2</sub> slope	-0.1 $\pm$ 5.6	(-2.1 to 1.9)	33	-1.9 $\pm$ 15.9	(-7.7 to 3.8)	32	0.55	1.8 $\pm$ 3.0	(-4.2 to 7.8)	65
Echocardiography										
sPAP (mmHg)	5.8 $\pm$ 14.2	(1.0 to 10.6)	36	-4.0 $\pm$ 12.5	(-8.1 to 0.1)	38	0.002	9.8 $\pm$ 3.1	(3.6 to 16.0)	74
TAPSE (mm)	3.2 $\pm$ 29.2	(-0.1 to 0.1)	41	5.5 $\pm$ 41.7	(-0.1 to 0.2)	38	0.77	-2.4 $\pm$ 8.2	(-18.6 to 13.9)	79
RA area (cm <sup>2</sup> )	-0.2 $\pm$ 6.7	(-2.5 to 2.1)	36	0.4 $\pm$ 6.0	(-1.6 to 2.3)	39	0.70	-0.6 $\pm$ 1.5	(-3.5 to 2.4)	75
RV area (cm <sup>2</sup> )	0.3 $\pm$ 2.1	(-0.5 to 1.1)	29	-0.3 $\pm$ 3.1	(-1.5 to 0.9)	28	0.41	0.6 $\pm$ 0.7	(-0.8 to 2.0)	57
Quality of life										
Physical summation score	3.9 $\pm$ 13.2	(0.2 to 7.7)	50	6.4 $\pm$ 14.4	(8.1 to 18.1)	49	0.37	2.5 $\pm$ 2.8	(-8.0 to 3.0)	99
Mental summation score	2.2 $\pm$ 11.6	(-1.1 to 5.5)	50	4.3 $\pm$ 11.7	(20.6 to 38.6)	49	0.38	2.1 $\pm$ 2.4	(-6.8 to 2.5)	99
Physical functioning	4.3 $\pm$ 13.2	(0.5 to 8.1)	48	8.1 $\pm$ 18.1	(3.0 to 13.3)	50	0.23	3.8 $\pm$ 3.2	(-10.2 to 2.5)	104
Physical role functioning	6.1 $\pm$ 42.2	(-5.5 to 17.8)	53	20.6 $\pm$ 38.6	(9.7 to 31.5)	51	0.07	14.5 $\pm$ 7.9	(-30.2 to 1.3)	104
Bodily pain	0.7 $\pm$ 26.7	(-6.7 to 8.1)	53	3.4 $\pm$ 18.3	(-1.8 to 8.5)	51	0.55	2.7 $\pm$ 4.5	(-11.6 to 6.2)	104
General health perceptions	3.0 $\pm$ 14.1	(-0.9 to 6.9)	53	0.6 $\pm$ 16.6	(-4.1 to 5.3)	51	0.23	-2.4 $\pm$ 3.0	(-3.6 to 8.4)	98
Vitality	2.5 $\pm$ 14.2	(-1.5 to 6.4)	53	4.6 $\pm$ 11.3	(1.4 to 7.8)	51	0.39	2.2 $\pm$ 2.5	(-7.2 to 2.9)	104
Social role functioning	0.1 $\pm$ 21.1	(-5.8 to 5.9)	53	6.6 $\pm$ 17.8	(1.6 to 11.6)	51	0.09	6.6 $\pm$ 3.8	(-14.1 to 1.0)	104
Emotional role functioning	4.7 $\pm$ 35.5	(-5.6 to 1.4)	53	8.5 $\pm$ 34.5	(1.7 to 8.7)	51	0.58	3.8 $\pm$ 6.9	(-17.4 to 9.8)	104
Mental health	-2.1 $\pm$ 12.8	(-5.6 to 1.4)	53	5.2 $\pm$ 12.5	(1.7 to 8.7)	51	0.004	7.3 $\pm$ 2.5	(-12.2 to -2.4)	104

In case of missing values, sample sizes are given in the column of n.

6MWT, 6-min walk test; NT-proBNP, N-terminal pro brain natriuretic peptide; O<sub>2</sub>, oxygen; RA, right atrial; RV, right ventricular; SaO<sub>2</sub>, oxygen saturation; SD, standard deviation; sPAP, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion; VE/VCO<sub>2</sub>, minute ventilation/carbon dioxide production; VO<sub>2</sub>, oxygen consumption.

\*P-value: significance of changes compared with baseline between groups.

**Table 3** Adverse events with occurrence  $\geq 5\%$

Adverse events	Group		Total
	Control (n = 47)	Training (n = 52)	
Arrhythmia of any kind	5	3	8
Respiratory infection	3	4	7
Total	8	7	15
Serious adverse events			
Diabetes, decompensated	0	1	1
Oedema, generalised	0	1	1
Haemoptysis	1	0	1
Stroke	0	1	1
Total	1	3	4

parameters which need to be interpreted with caution due to missing data. Especially for haemodynamic changes with exercise training in PH further data, preferably including right heart catheterization, are needed.

It is intrinsically not possible to blind a training study. However, investigators involved in data analysis were blinded as far as possible including clinical data and QoL assessments. Due to organizational reasons, not all centres were, however, able to perform blinded assessments of 6MWD, though the walking distance of previous assessments was not known to the investigators.

Total number of AEs did not differ between groups, though patients of the training group had a higher frequency of serious AEs and a higher dropout rate during the study. None of the AEs or serious AEs were stated to be related to the training intervention.

For safety concerns severely deconditioned patients with very restricted mobility range were not included in this study. Thus, we cannot exclude a selection bias towards more active patients.

As most of the patients in the control group were offered to participate in the exercise training programme after having finished their final examination, long-term data for comparison between exercise training and control group were not available. No daily physical activity measurements were part of the protocol. Thus, it is not possible to quantify whether general activity increased after the exercise training.

Conclusions

This is the first multicentre and the largest randomized, controlled study so far, reporting the beneficial effects of exercise training on 6MWD, QoL, and oxygen consumption in patients with PH. Study results are in line with previous studies. Exercise training was successfully implemented in all participating centres, including PH expert centres as well as experienced rehabilitation facilities. Further large multicentre studies are needed to investigate the haemodynamic effects of this intervention on different subtypes of PH.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Funding

This work was supported by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (PI17/1515), Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea. ‘Una manera de hacer Europa’. H.D. is a post-doctoral research fellow of the FWO-Flanders. Actelion Germany supported PH experts to visit Heidelberg to observe the training programme. The exercise training study in Glasgow was funded jointly by Actelion, MSD, and PHA-UK.

**Conflict of interest:** E.G. reports speaker fees from Actelion, Bayer/MSD, Bial, OrphaSwiss GmbH, Medscape and research grants from Actelion, Bayer/MSD, GSK, United Therapeutics, Novartis, Bellerophon, OMT, Pfizer, and Reat outside of the submitted work. A.M., A.P., C.A.E., R.N., S.S., M.B., M.S., S.G., E.P., E.J., A.C., A.A.S., A.M.M., J.A.B., A.R., M.S., S.G.V., H.D., and E.B. have nothing to disclose. N.B. reports speaker fees from Actelion, Bayer, and MSD outside the submitted work. S.U. reports research grants from Swiss National Science Foundation, Zurich Lug, Actelion SA, OrphaSwiss, Johnson and Johnson, and personal fees from Actelion SA, MSD Swiss, and Johnson and Johnson outside the submitted work. L.G. reports speaker fees from Actelion a Janssen pharmaceutical company and advisory board fee from UAB Johnson and Johnson. G.K. reports personal fees and non-financial support from Actelion, Bayer, GSK, MSD, Boehringer Ingelheim, Novartis, Chiesi, Vitalaire, Ferrer, and AOP outside the submitted work. H.O. reports personal fees from Actelion, Boehringer, Chiesi, GSK, MSD, Novartis, Menarini, MedUpdate, Bayer, research grants from Acteklion, Inventiva and non-financial support from Boehringer and Ludwig Boltzmann Institute for Lung Vascular Research outside the submitted work. I.B. reports personal fees from Actelion, MSD-Merck outside the submitted work. M.S. reports grants from Netherlands Lung Foundation, Stichting Astma Bestrijding, Astra Zeneca, Boehringer Ingelheim and personal fees from Astra Zeneca, Boehringer Ingelheim outside the submitted work. F.F. reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and TEVA and research grants from AstraZeneca and Novartis outside the submitted work. A.V.N. reports speaker fees from ferrer and Johnson and Johnson outside the submitted work. M.D. reports research grants; investigator, speaker, and consultant fees from Actelion/J&J, investigator, speaker, and consultant fees from Bayer, speaker and consultant fees from Bayer, investigator fees from Reata, investigator and consultancy fees from Bellerophon, consultancy fees from Acceleron outside the submitted work. M.J. reports research grants from Actelion, MAS, and PHA-UK for the submitted work.

References

1. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJH, Grotjohan HP, Twisk JWR, Bogaard H-J, Boonstra A, Postmus PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J* 2009;**34**:669–675.

2. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth HJ, Opitz C, Ulrich S, Egenlauf B, Grünig E. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. *Eur Heart J* 2016;**37**:35–44.

3. Mereles D, Ehlken N, Kreusser S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzappel N, Opitz C, Winkler JRG, Herth FFJ, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation* 2006;**114**:1482–1489.

4. Chan L, Chin LM, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA, Connors G, Weir NA, Drinkard B, Lamberti J, Keyser RE. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. *Chest* 2013;**143**:333–343.
5. González-Saiz L, Fiuza-Luces C, Sanchis-Gomar F, Santos-Lozano A, Quezada-Loaiza CA, Flox-Camacho A, Munguía-Izquierdo D, Ara I, Santalla A, Morán M, Sanz-Ayan P, Escribano-Subías P, Lucia A. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: the WHOLEi+12 trial. *Int J Cardiol* 2017;**231**:277–283.
6. Ley S, Fink C, Risse F, Ehlken N, Fischer C, Ley-Zaporozhan J, Kauczor HU, Klose H, Gruenig E. Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension. *Eur Radiol* 2013;**23**:324–331.
7. Weinstein AA, Chin LM, Keyser RE, Kennedy M, Nathan SD, Woolstenhulme JG, Connors G, Chan L. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. *Respir Med* 2013;**107**:778–784.
8. Grünig E, Eichstaedt C, Barberà J-A, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. *Eur Respir J* 2019;**53**:1800332.
9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J* 2015;**46**:903–975.
10. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J* 2019;**53**:1801889.
11. Grünig E, Benjamin N, Kruger U, Kaemmerer H, Harutyunova S, Olsson KM, Ulrich S, Gerhard F, Neurohr C, Sablotzki A, Halank M, Kabitz HJ, Thimm G, Fliegel KG, Klose H. Allgemeine und supportive Therapie der pulmonal arteriellen Hypertonie [General and supportive therapy of pulmonary arterial hypertension]. *Dtsch Med Wochenschr* 2016;**141**:S26–S32.
12. Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. *BMC Pulm Med* 2015;**15**:40.
13. Morris NR, Kermeeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. *Cochrane Database Syst Rev* 2017;**1**:CD011285.
14. Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD. Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis. *Circ Heart Fail* 2015;**8**:1032–1043.
15. Yuan P, Yuan X-T, Sun X-Y, Pudasaini B, Liu J-M, Hu Q-H. Exercise training for pulmonary hypertension: a systematic review and meta-analysis. *Int J Cardiol* 2015;**178**:142–146.
16. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2019;**73**:1494–1563.
17. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. *Thorax* 1984;**39**:818–822.
18. American Thoracic Society, Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;**166**:111–117.
19. Nagel C, Marra AM, Benjamin N, Blank N, Cittadini A, Coghlan G, Distler O, Denton CP, Egenlauf B, Fiehn C, Fischer C, Harutyunova S, Hoeper MM, Lorenz HM, Xanthouli P, Bossone E, Grünig E. Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary arterial pressures. *Arthritis Rheumatol* 2019;**71**:805–816.
20. Galie N, Manes A, Palazzini M. Exercise training in pulmonary hypertension: improving performance but waiting for outcome. *Eur Heart J* 2016;**37**:45–48.
21. Sitbon O, Gombert-Maitland M, Granton J, Lewis MJ, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. *Eur Respir J* 2019;**53**:1801908.
22. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. *Circulation* 2012;**126**:349–356.
23. Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grünig E, Seyfarth HJ, Kolditz M, Wieder G, Hoffken G, Kollner V. Exercise capacity affects quality of life in patients with pulmonary hypertension. *Lung* 2013;**191**:337–343.
24. Mathai SC, Puhon MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012;**186**:428–433.
25. Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. *Chest* 2017;**151**:90–105.
26. Liu HL, Chen XY, Li JR, Su SW, Ding T, Shi CX, Jiang YF, Zhu ZN. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. *Chest* 2016;**150**:353–366.
27. Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Soricther S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C. Safety and efficacy of exercise training in various forms of pulmonary hypertension. *Eur Respir J* 2012;**40**:84–92.
28. Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilt R, Rubenfire M, Barst RJ. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. *Vascul Pharmacol* 2005;**43**:36–39.